

REMARKS

Applicants received a "Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures" dated November 25, 2002 (copy enclosed). The Notice to Comply stated that applicants must provide computer readable and paper copies of a "Sequence Listing" for the application, as set forth in compliance with 37 C.F.R. 1.821-1.825.

Applicants respond to the Notice as follows:

1. Applicants hereby provide a paper copy of a "Sequence Listing" (enclosed), in compliance with 37 C.F.R. § 1.821(c).
2. Applicants hereby provide a computer readable form (CRF) copy of the "Sequence Listing" on compact disk (enclosed), in compliance with 37 C.F.R. 1.821(e).
3. Applicants have requested that the specification be amended (a) to insert the sequence listing, as a separate part of the disclosure, immediately before the claims, and (b) to insert corresponding sequence identifiers (i.e., SEQ ID Nos.) at appropriate locations in the specification.
4. Applicants hereby state that the content of the paper and computer readable copies of the "Sequence Listing" are the same, and that they contain no new matter.

Applicants believe that they have fully complied with the requirements of the Notice to Comply and, more generally, with the requirements for patent applications containing nucleotide sequence and/or amino acid sequence disclosures. However, if the Examiner disagrees or has any questions, or if a telephone interview would in any way advance prosecution of this application, the Examiner is urged to contact the undersigned attorney.

CERTIFICATE OF MAILING

I hereby certify that this correspondence, including the compact disk with Sequence Listing, is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Box Sequence, Washington, D.C. 20231 on December 26, 2002.



Respectfully submitted,

KOLISCH HARTWELL, P.C.

James R. Abney

James R. Abney
Registration No. 42,253
520 S.W. Yamhill Street, Suite 200
Portland, Oregon 97204
Telephone: (503) 224-6655
Facsimile: (503) 295-6679
Attorney for Assignee

VERSION WITH MARKINGS TO SHOW CHANGES MADE

The description has been amended at page 37, lines 9-18, as follows (material to be inserted is in **bold and underline**, material to be deleted is in **[brackets and strikeout]**):

This example describes experiments to characterize binding between MM-Ga and the following mono-serine fluorescein-labeled peptide tracer:

fluorescein-Leu-Arg-Arg-Ala-Ser-Leu-Gly (**SEQ ID NO: 1**)

This peptide is termed a “Kemptide,” and the fluorescein-labeled peptide is termed a “fluo-Kemptide.” These experiments use cAMP-dependent protein kinase A (PKA, Promega) as the enzyme and fluo-Kemptide as the substrate. These experiments show the utility of the MM-Ga system for detection of phosphorylated serine and the presence and/or activity of serine/threonine kinases and phosphatases.